Main Indications

Aflamil is a non-steroidal anti-inflammatory drug (NSAID) containing the active substance aceclofenac. It is primarily used to manage symptoms of chronic inflammatory conditions and acute painful episodes related to the musculoskeletal system. The medication works by inhibiting the production of prostaglandins, which are chemicals in the body responsible for mediating pain and inflammation.

Chronic Joint Conditions

Aflamil is commonly prescribed for the long-term management of chronic joint disorders. Its primary applications include:

• Osteoarthritis: It helps alleviate the pain and joint stiffness associated with the gradual breakdown of joint cartilage.
• Rheumatoid Arthritis: It reduces the inflammation, swelling, and joint pain caused by this autoimmune condition.
• Ankylosing Spondylitis: It treats the pain and stiffness in the spine and sacroiliac joints characteristic of this inflammatory disease.

Acute Musculoskeletal Pain

Beyond chronic conditions, Aflamil is used for the relief of acute pain and inflammation affecting the muscles and skeletal structure. This includes conditions such as:

• Lower back pain (lumbago)
• Dental pain
• Painful menstruation (dysmenorrhea)
• Joint pain caused by trauma or strain

Benefits of Treatment

The goal of treatment with Aflamil is to improve the patient's quality of life by addressing the physical limitations caused by pain. The main therapeutic benefits include:

• Reduction of Inflammation: By targeting the inflammatory process at the source, it helps reduce localized swelling and heat in affected joints.
• Pain Relief: It provides significant analgesic effects, allowing for better management of both constant and movement-related pain.
• Improved Mobility: By reducing stiffness and discomfort, the medication helps restore a greater range of motion, enabling patients to perform daily activities more comfortably.

Eligibility for Aflamil (Aceclofenac)

The official population eligibility for Aflamil, a Nonsteroidal Anti-inflammatory Drug (NSAID), is determined by regulatory criteria that define who is permitted to use the medicine and who is absolutely excluded. Use is primarily established for adults (18 years and older).

Contraindicated Populations (Must Not Use)

Aflamil is formally contraindicated in patients with [1.1, 1.2]:

• Severe organ failure (hepatic, renal, or severe heart failure).
• Active or recurrent gastrointestinal bleeding/ulceration or a history of perforation related to prior NSAID use.
• Hypersensitivity reactions to Aceclofenac, aspirin, or any other NSAID.
• Established cardiovascular disease, including ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Third trimester of pregnancy.

Restricted and Conditional Use

The medicine is not recommended for children and adolescents under 18 due to insufficient clinical data [1.2, 2.2].

Conditional use and close surveillance are required for the elderly and for patients with mild renal impairment, mild-to-moderate hepatic impairment, or mild congestive heart failure [2.1, 2.2]. The drug is not recommended for breastfeeding women or those attempting to conceive [4.4, 4.5].

Official Interactions with other medicines and products

The official regulatory profile for Aflamil (Aceclofenac) establishes specific constraints, primarily related to pharmacodynamic risk and altered drug exposure.

Interaction-Related Restrictions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, must be avoided due to a documented increased risk of serious gastrointestinal events. Interaction with Mifepristone requires a mandatory timing separation; the drug should not be used for 8–12 days following mifepristone administration to maintain its efficacy.

Pharmacodynamic Interactions and Additive Risk

Co-administration with anti-coagulants (e.g., Warfarin) enhances their effects, resulting in an officially documented increased risk of bleeding and hemorrhage. The combination with systemic corticosteroids also increases the risk of gastrointestinal ulceration. Furthermore, the antihypertensive effect of ACE inhibitors or ARBs and the natriuretic effect of diuretics are both documented to be diminished.

Altered Pharmacokinetic Exposure

Aceclofenac causes decreased elimination of certain co-administered substances, including Lithium and Methotrexate, resulting in officially documented increased plasma concentrations of those drugs.

Timing and Population Notes

The interaction with Methotrexate requires caution if administered within 24 hours. For the oral tablet, food reduces the rate of absorption but does not alter the total extent of absorption. Interactions may be more clinically significant in the elderly and in patients with cardiac, hepatic, or renal impairment, as documented in official labeling.

How Aflamil Works: Mechanism of Action

Aflamil (Aceclofenac) influences biological systems by coordinating the modulation of key enzymes and mediators involved in the inflammatory cascade. The primary mechanism of action involves Aceclofenac acting as a preferential inhibitor of the enzyme Cyclooxygenase-2 (COX-2), which is induced at sites of tissue distress.

By slowing down COX-2 activity, the drug limits the local biosynthesis of pro-inflammatory messengers, primarily prostaglandins. This molecular action leads to a decrease in the PGE2-mediated sensitization of peripheral nociceptors and a reduction in microvascular permeability.

Separately, the drug and its active metabolites modulate other signaling proteins, such as Interleukin-1beta and TNF-alpha. This secondary influence further limits the escalation of the overall physiological response to inflammatory stimuli. Additionally, Aceclofenac exerts a distinct mechanistic influence within joint tissues by engaging pathways that influence the synthesis of glycosaminoglycans within the cartilage matrix, contributing to the processes of cartilage homeostasis.

Administration and Dosage Forms

The administration of Aflamil (Aceclofenac) involves the use of the 100 mg film-coated tablet. This tablet is intended for the oral route to achieve systemic absorption, though the active ingredient is also available in topical cream or gel forms for localized use.

Standard Dosage for Adults

The standard adult posology involves a total daily dose of 200 mg. This amount is administered as two separate 100 mg doses per day, which establishes a twice-daily (b.i.d.) frequency pattern. When taking the tablets, they must be swallowed whole with a sufficient quantity of liquid and should not be crushed, broken, or chewed. It is generally recommended that administration occur with or immediately after food.

Treatment Principles and Special Populations

Use of the medication is guided by the principle of administering the lowest effective dose for the shortest duration required to manage symptoms, with the necessity of continued therapy subject to periodic re-evaluation. Dosing modifications are outlined for certain populations:

• Hepatic Impairment: Patients with diagnosed hepatic impairment initiate treatment at a reduced total daily dose of 100 mg.
• Elderly and Renal Impairment: No routine dose adjustment is considered necessary for the elderly or for individuals with mild renal impairment.
• Pediatric Use: The use of Aflamil is not recommended in children and adolescents under 18 years of age due to insufficient supporting clinical data.

Research evidence / Overview of studies for Aflamil

---

Osteoarthritis

Research on Aflamil for osteoarthritis, which is a common condition involving joint pain and stiffness, primarily uses randomized controlled trials. These trials compare Aflamil to a placebo (a dummy pill) or to other similar medications already on the market. These are generally considered a robust method for investigating a medication.

The findings from these studies suggest that Aflamil was associated with improvements in the symptoms of osteoarthritis, particularly in measures of pain and the joint's physical function. For example, some research has indicated that the group taking Aflamil showed improvements in measures of pain intensity and general functional capacity. In comparisons with other non-steroidal anti-inflammatory drugs (NSAIDs), Aflamil's effects on pain and function were generally similar to some alternatives.

The positive observations from trials were typically short-term; the long-term effects of using Aflamil for many years in people with osteoarthritis have not been extensively explored in large-scale studies. The research mainly focuses on short-to-medium-term use (from a few weeks up to a few months). More information is needed to understand the potential impact over very long periods, and research does not definitively "prove" a benefit, but rather indicates a likely positive effect on symptoms.

---

Rheumatoid Arthritis

For rheumatoid arthritis, which is a long-term condition causing inflammation in the joints, the evidence is also largely based on randomized controlled trials. These studies have investigated the effect of Aflamil on joint pain, tenderness, and morning stiffness that are characteristic of this disease.

Studies suggest that the group taking Aflamil reported improvements in several key areas for people with rheumatoid arthritis. Findings have indicated an association with lower scores for spontaneous morning pain and pain upon movement, as well as a lower number of tender and swollen joints, when compared to a placebo. In comparisons with other established treatments, the research generally suggests similar findings in these clinical symptoms.

A key limitation in the research for rheumatoid arthritis is that most studies focus on symptom management rather than halting or slowing the disease's progression. Furthermore, while the general population with rheumatoid arthritis has been studied, there is limited specific evidence differentiating the drug’s effects in special groups, such as elderly patients with more severe or long-standing disease, or those with other significant health issues.

---

Ankylosing Spondylitis

Ankylosing spondylitis is an inflammatory disease primarily affecting the spine and large joints. Research exploring Aflamil's use in this condition has also involved controlled studies, typically comparing it to placebo or other NSAIDs. The focus of these studies is on measures of back pain, stiffness, and overall spinal movement.

The evidence so far suggests Aflamil was associated with positive findings in managing the symptoms of ankylosing spondylitis. Findings have reported lower scores for night pain, morning stiffness, and general pain intensity in the group taking Aflamil. Some studies comparing it to other treatments have suggested that its effect on pain and spinal mobility is similar to certain other NSAIDs.

However, the amount of research dedicated solely to Aflamil in ankylosing spondylitis is more limited than for the other two indications. While the existing studies report certain observations regarding symptom relief, more research is needed, especially large, long-term studies, to better understand its overall role in the long-term care of this condition. The current evidence provides a preliminary understanding, but not a full picture of all potential findings or limitations.

Key Studies & References

1. Aflamil for Symptomatic Relief in Active Rheumatoid Arthritis: A Phase 3, Multi-Center Study
2. National Institute for Health and Care Excellence (NICE) Guideline: Management of Rheumatoid Arthritis in Adults

Common questions about Aflamil (FAQ)

---

Q: How quickly should I expect Aflamil to start working?

Official information derived from pharmacokinetic studies—which examine how the drug moves through the body—indicates that the highest concentration of the active ingredient in the bloodstream is typically reached about 1.25 to 3.00 hours after taking the tablet. This timeframe indicates when the peak concentration, which is associated with the maximum effect, is generally achieved.

---

Q: How long does the effect of one dose of Aflamil usually last?

The duration of the drug’s presence is described by its mean plasma elimination half-life, which official information states is approximately 4 hours. This data is one of the factors considered in establishing the recommended frequency for use.

---

Q: Can Aflamil be taken on an empty stomach?

The official documentation provides the advice to take the tablet preferably with or immediately after food. While regulatory studies indicate that taking the drug when fasting does not affect the total amount of absorption, it does affect the rate. This practice is consistent with standard use guidance for this class of medication.

---

Q: What happens if I miss a scheduled dose of Aflamil?

Regulatory information describes that a policy exists for managing a missed dose. Generally, a missed dose is taken upon remembering, unless the next dose is due shortly, in which case the missed dose is skipped. The compensation with a double dose is officially stated as not recommended.

---

Q: Does Aflamil cause drowsiness or affect my ability to drive?

Official documents list undesirable effects such as dizziness, drowsiness, fatigue, and visual disturbances as possible with this class of medication. If a person is affected by these specific side effects, official documents advise against driving or operating machinery. The regulatory guidance is for individuals to be aware of their personal reaction to the medication before driving or operating machinery.

---

Q: How long can a person usually be on Aflamil treatment?

Official safety guidance states that the medication should be used for the shortest duration possible and at the lowest effective dose. This is because documented risks, particularly cardiovascular risks, may increase with both the dose and the duration of exposure.

---

Q: What is the expected timeline for improvement when using Aflamil for inflammation?

The regulatory text emphasizes that a patient's response and their need for continued therapy should be re-evaluated periodically by a healthcare professional. There is no single defined timeline for improvement in official documents; the response can vary based on the treated condition and the individual.

---

Q: Can Aflamil affect kidney function?

Official safety information indicates that the use of NSAIDs may potentially lead to a dose-dependent reduction in certain protective functions in the body, which can result in the deterioration of kidney function. For patients on long-term treatment, regular monitoring of renal function is advised in regulatory guidelines.

---

Q: Are there different strengths or dosages of Aflamil available?

The main formulation described in official documents is the 100 mg film-coated tablet for oral use. In some regions, other dosage forms may be available, such as a 200 mg controlled-release tablet.

---

Q: What is the main difference between Aflamil and over-the-counter pain relievers?

Aflamil (Aceclofenac) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is generally regulated as a prescription-only medicine (POM/Rx-only) in many regions. This regulatory status is generally associated with the drug's safety profile, where the potential for serious adverse events requires the oversight of a healthcare professional.

---

Q: Is Aflamil considered a narcotic or opioid?

No, official drug documents classify Aflamil (Aceclofenac) as a Nonsteroidal Anti-inflammatory Drug (NSAID). The drug is not chemically or functionally related to narcotics or opioids.

---

Q: Are there any long-term risks associated with using Aflamil?

Regulatory information notes that cardiovascular risks and the potential for effects on the gastrointestinal system may increase with the duration of exposure. For patients receiving long-term treatment, official guidelines recommend close monitoring of organs such as the kidneys and liver, as well as blood counts.

---

Q: What foods or drinks should be avoided while taking Aflamil?

Official documents do not list specific foods to avoid, but taking the tablet with or after food is advised. The consumption of alcohol is frequently described in regulatory guidance for NSAID-class drugs as being associated with an increased risk of serious gastrointestinal bleeding.

---

Q: What is the main reason Aflamil is only available by prescription?

The drug is regulated as a prescription-only medicine in many regions due to the documented potential for serious adverse reactions. These potential reactions, which include documented cardiovascular risks and gastrointestinal bleeding, are why professional oversight is required to manage the use of the drug.

---

Q: Can Aflamil affect the results of any lab tests?

Regulatory documents state that individuals receiving long-term treatment should be regularly monitored for changes in specific tests. These include renal function tests (kidneys), liver function tests, and blood counts. The requirement for this monitoring indicates the potential for these values to be affected during treatment.

---

Q: What is the risk of dependence or addiction with Aflamil?

Official drug documents classify Aflamil (Aceclofenac) as a Nonsteroidal Anti-inflammatory Drug (NSAID). Since it is not classified as an opioid or narcotic, regulatory safety information does not describe any risk of dependence or addiction.

---

Q: Does the time of day I take Aflamil matter?

The standard posology described in official regulatory documents specifies taking the total daily dose as two separate doses. This is typically directed as one tablet in the morning and one in the evening to maintain consistent levels of the active ingredient throughout the day.

---

Q: Does Aflamil cause fluid retention?

Official safety documents report that fluid retention and oedema (swelling due to fluid retention) have been associated with NSAID therapy. Official guidelines describe that monitoring is required for patients with a history of heart conditions or high blood pressure.

---

Q: Are there any common interactions between Aflamil and depression medications?

Official interaction information lists certain depression medications known as selective serotonin-reuptake inhibitors (SSRIs) as substances that may pose an increased risk. Co-administration of Aflamil with SSRIs is documented to potentially increase the risk of ulceration or bleeding.

---

Q: Do children ever take Aflamil, and what are the limitations?

Official regulatory information states that the use of Aflamil is not recommended in children and adolescents under 18 years of age. This restriction is based on a lack of sufficient supporting clinical data for this specific population.

---

Q: Is it common for Aflamil to be used after surgery?

Regulatory information for Aflamil lists its purpose for addressing inflammation and pain, including in cases of post-trauma or post-operative inflammations. Its use in managing pain following surgical procedures is an officially acknowledged indication.

How to Store and Dispose of Aflamil?

Official regulatory documents define specific requirements for the storage and disposal of Aflamil, which contains diclofenac.

Storage & Disposal Domain	Official Requirement
Temperature & Light	Store in a cool, dry, and well-ventilated place, in accordance with national regulations.
Security & Handling	Keep out of the reach of children and, where required, store locked up. Keep in the original, tightly closed container and away from strong oxidizing agents.
Disposal	Due to the documented risk to the aquatic environment, unused medicine and waste material must not be discharged to sewer systems.

Disposal instructions require contents and container to be handled in accordance with all local, regional, and national waste regulations, explicitly mandating that environmental release must be avoided.